Answers- From yesterdays post ( True or False Questions)
#1 GLP-1 agonist is the only diabetes medication that stimulates glucose sensitive insulin release.
True _x_ False __
Glucose sensitive insulin release is one of the best features of GLP-1 agonist. This means that
insulin is released from the pancreas Beta cells in response to increasing glucose levels . This effect
along with restoring the early rapid insulin release restores the Beta cell to a more normal function
and reduces the risk of hypoglycemia and preserves Beta cell function.
Older diabetes medicines ( sulfonynlureas-such as glimepiride , glyburide, glipazide and others)
cause a continuous insulin release irrespective of meals , increase the risk of hypoglycemia and are
thought to essentially burn out the Beta cells.
#2 GLP-1 may be responsible for 50 to 70 % of total insulin secreted after a meal .
True _x_ False __
" glucose sensitive insulin release"
#3 People with Type 2 Diabetes have a deficiency of GLP-1.
The exact cause of this deficiency is not clear. Obesity may play a role in the process.
#4 GPL-1 effectiveness is normal in patients with Type 2 Diabetes.
The other benefit of GLP-1 agonist is weight loss
Diabetes Care May 12, 2012 vol 35 no. 5 page 955-958
Baseline factors Associated with glycemic control and weight loss when exenatide ( Byetta )
was added to optimized insulin Glargine ( Lantus ) in Type 2 Diabetes
This study was done in obese patients with long standing diabetes 9 to 15 years duration who required insulin for adequate glucose control. The use of insulin usually results in more weight gain, In this study the group receiving Exenatide plus lantus insulin had greater reduction in their A1c with the added benefit of weight loss compared to the insulin only group.
Have Fun. Be Smart talk to your doctor about some of the newer Diabetes medications
David Calder, MD